Search
Search
Search results 24
AmoyDx® Essential NGS panel got approval from Chinese authority
AmoyDx® Essential NGS panel was approved by Chinese National Medical Products Administration (NMPA) on November 20, 2018, for qualitative detection of gene mutations in patients with Non-Small Cell
News & Events
Amoy Diagnostics achieved China NMPA Approval of Multi-Genes Mutations Detection Kit
Amoy Diagnostics Co., Ltd. (AmoyDx, SHE:300685) announced that NMPA(National Medical Products Administration)approved its Multi-Genes Mutations Detection Kit on Aug 24, 2018.
News & Events
Merck and AmoyDx Collaborate to Bring Liquid Biopsy RAS Biomarker Testing to China
· Liquid biopsy RAS biomarker test based upon AmoyDx's real-time PCR technology, ADx-SuperARMS®, will be made available in China in 2017 · Merck is the first pharmaceutical company to collaborate with multiple
News & Events
AmoyDx ROS1 Diagnostics Test Contributed to a Phase 2 Clinical Study of Crizotinib in Lung Cancer
June 14, 2016, Xiamen, China -- Amoy Diagnostics Co, Ltd. (AmoyDx), a leading provider of cancer molecular diagnostic products and services, announced today that its AmoyDx®ROS1 test successfully supported
News & Events
Amoy Diagnostics and Illumina Enter Strategic Collaboration for Next-Generation Sequencing Cancer Diagnostics in China
XIAMEN, China & SAN DIEGO--(BUSINESS WIRE)--Amoy Diagnostics Co. Ltd. (ADx) and Illumina, Inc. (NASDAQ: ILMN) today announced a strategic collaboration to accelerate the adoption of precision medicine
News & Events
KRAS Mutation Detection Kit
PRODUCTS
KRAS/NRAS Mutations Detection Kit
PRODUCTS
KRAS/NRAS/BRAF Mutations Detection Kit
PRODUCTS
Essential NGS Panel
A precise NGS panel, focusing on 10 genes which have clear evidence to the targeted therapy.
PRODUCTS
KRAS-L2-02 Targeted therapies in colorectal cancer—an integrative view by PPPM
DOWNLOAD
KRAS-L2-01 Role of the pretreatment 18F-fluorodeoxyglucose positron emission tomography maximal standardized uptake value
DOWNLOAD
EGFR-L2-07 KRAS-L2-03 BRAF-L2-03 PIK3CA-L2-01 ROS1-L2-02 Molecular alterations and clinical prognostic factors for
DOWNLOAD
MSDS-Super-ARMS KRAS&NRAS&BRAF-201804
DOWNLOAD
BRAF-L2-01 Comparison of Targeted Next-Generation Sequencing (NGS) and Real-Time PCR in the Detection of EGFR, KRAS, and BRAF
DOWNLOAD
MSDS-KRAS19-201804
DOWNLOAD
Super-ARMS® KRASNRASBRAF Mutations Detection Kit-B2.2-24T
DOWNLOAD
MSDS-KRAS&NRAS&BRAF Panel-201804
DOWNLOAD
AmoyDx® KRASNRASBRAF Mutations Detection Kit-P2.1-6T
DOWNLOAD
MSDS-KRAS&NRAS Panel-201804
DOWNLOAD
AmoyDx® KRASNRAS Mutations Detection Kit-B2.2-24T
DOWNLOAD
KRAS-L1-01 BRAF-L1-02 KRAS and BRAF gene mutations and DNA mismatch repair status in Chinese colorectal carcinoma patients
DOWNLOAD
KNBP-L1-01 Molecular spectrum of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese colorectal cancer patients_ analysis of 1,110
DOWNLOAD
AmoyDx® KRAS Mutation Detection Kit-B2.3-24T
DOWNLOAD
6. KRAS-2017
DOWNLOAD
no more...
AmoyDx® Essential NGS panel got approval from Chinese authority
AmoyDx® Essential NGS panel was approved by Chinese National Medical Products Administration (NMPA) on November 20, 2018, for qualitative detection of gene mutations in patients with Non-Small Cell
News & Events
Amoy Diagnostics achieved China NMPA Approval of Multi-Genes Mutations Detection Kit
Amoy Diagnostics Co., Ltd. (AmoyDx, SHE:300685) announced that NMPA(National Medical Products Administration)approved its Multi-Genes Mutations Detection Kit on Aug 24, 2018.
News & Events
Merck and AmoyDx Collaborate to Bring Liquid Biopsy RAS Biomarker Testing to China
· Liquid biopsy RAS biomarker test based upon AmoyDx's real-time PCR technology, ADx-SuperARMS®, will be made available in China in 2017 · Merck is the first pharmaceutical company to collaborate with multiple
News & Events
AmoyDx ROS1 Diagnostics Test Contributed to a Phase 2 Clinical Study of Crizotinib in Lung Cancer
June 14, 2016, Xiamen, China -- Amoy Diagnostics Co, Ltd. (AmoyDx), a leading provider of cancer molecular diagnostic products and services, announced today that its AmoyDx®ROS1 test successfully supported
News & Events
Amoy Diagnostics and Illumina Enter Strategic Collaboration for Next-Generation Sequencing Cancer Diagnostics in China
XIAMEN, China & SAN DIEGO--(BUSINESS WIRE)--Amoy Diagnostics Co. Ltd. (ADx) and Illumina, Inc. (NASDAQ: ILMN) today announced a strategic collaboration to accelerate the adoption of precision medicine
News & Events
no more...
Inquiry
* Required information
Manage your account info
Change your password